Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0393 • ACR Convergence 2022
Are We Meeting Patients’ Treatment Goals with Guideline-Based Therapy for Psoriatic Arthritis?
Christeen Samuel¹, Laura Prichett¹, Thomas Grader-Beck¹, Uzma Haque¹, John Miller¹, Suzanne Grieb² and Ana-Maria Orbai³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine and School of Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Treatment success from the patients' perspective has not been defined in psoriatic arthritis (PsA). The objective was to determine prevalence and associations of patient-reported…
Abstract Number: 0827 • ACR Convergence 2022
Unpublished Clinical Trials of Major Rheumatic Diseases
Connor Pedersen¹, Mike Putman², Erin Valley¹, Kathryn Henry³, Ali Duarte-Garcia⁴, Shikha Singla⁵ and Shannon Tai¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²The Medical College of Wisconsin, Milwaukee, WI, ³Medical College of Wisconsin, Manitowoc, WI, ⁴Mayo Clinic, Rochester, MN, ⁵MCW, Fox Point, WI
Background/Purpose: Randomized controlled trials (RCTs) provide high-quality evidence for treatment efficacy, but many RCTs remain unpublished. The objective of this study was to describe the…
Abstract Number: 1035 • ACR Convergence 2022
Efficacy of Guselkumab in Three Cohorts of Biologic-Naïve PsA Patients with Axial Involvement Defined Based on Imaging and Machine-Learning Criteria: Pooled Analysis of Two Phase 3 Studies
Philip J Mease¹, William Tillett², Sarah Ohrndorf³, Michelle Perate⁴, Mary Medysky⁵, Miriam Zimmermann⁶, May Shawi⁷, Emmanouil Rampakakis⁸, Paul Bird⁹, Alen Zabotti¹⁰, Atul Deodhar¹¹ and Dafna Gladman¹², ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Seattle, WA, ⁶Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹University of New South Wales, Sydney, Australia, ¹⁰Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR, ¹²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Evidence on the efficacy of advanced therapies for axial involvement in PsA (axPsA) is scarce, largely due to the lack of a widely accepted…
Abstract Number: 1207 • ACR Convergence 2022
Risk Factors for Major Cardiovascular Events (MACE) in Inflammatory Arthritis: A Time-dependent Analysis on the Inflammatory Burden, Use of DMARDs, NSAIDs, and Steroid
Huan Meng¹, Steven H Lam², Ho So¹ and Lai-shan Tam³, ¹The Faculty of Medicine, CUHK, Hong Kong, Hong Kong, ²The Chinese university of Hong Kong, Hong Kong, Hong Kong, ³The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: Inflammatory arthritis (IA) including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to systematic inflammation. To elucidate whether inflammatory…
Abstract Number: 1489 • ACR Convergence 2022
Incidence of Herpes Zoster Events After the Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis
Devy Zisman¹, Noa Hayat¹, Amir Haddad², Joy Feld³, Tal Gazitt¹, Idit Lavi¹, Ilan feldhamer⁴, ARNON DOV COHEN⁴ and Walid Saliba¹, ¹Carmel Medical Center, Haifa, Israel, ²Carmel Medical Centre, Haifa, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel, ⁴Clalit Health Services, Tel Aviv, Israel
Background/Purpose: The importance and efficacy of anti COVID-19 vaccine in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…
Abstract Number: 1599 • ACR Convergence 2022
Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Joseph Merola¹, Robert Landewé², Iain B McInnes³, Philip J Mease⁴, Christopher Ritchlin⁵, Yoshiya Tanaka⁶, Akihiko Asahina⁷, Frank Behrens⁸, Dafna Gladman⁹, Laure Gossec¹⁰, Richard Warren¹¹, Barbara Ink¹², Deepak Assudani¹², Rajan Bajracharya¹², Jason Coarse¹³ and Laura Coates¹⁴, ¹Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ²Amsterdam University Medical Center, Meerssen, Netherlands, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁷Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ⁸Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁰Sorbonne Université, Paris, France, ¹¹The University of Manchester, Manchester, United Kingdom, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. The phase 3 BE COMPLETE study assessed the efficacy…
Abstract Number: 2110 • ACR Convergence 2022
Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Laure Gossec¹, Mohamed Sharaf², Elke Theander³, Marlies Neuhold⁴, Paul Bergmans⁵, May Shawi⁶, Michelle Perate⁷, Christine Contré⁸ and Laura Coates⁹, ¹Sorbonne Université, Paris, France, ²Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ³Formerly at Janssen Scientific Affairs, LLC, Solna, Sweden, ⁴Takeda Europe & Canada Business Unit (EUCAN) Medical Affairs, Zurich, Switzerland; formerly at Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁵Formerly at Janssen, Breda, Netherlands, ⁶Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Formerly at Janssen Scientific Affairs, LLC, Issy-les-Moulineaux, France, Issy-les-Moulineaux, France, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic…
Abstract Number: 2126 • ACR Convergence 2022
Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials
Shawn Kwatra¹, Saakshi Khattri², Ahmad Amin³, Huzefa Photowala⁴, Ran Liu⁴, Byron Padilla⁵, Blair Kaplan⁴ and Dennis McGonagle⁶, ¹John Hopkins University, Baltimore, MD, ²Mount Sinai Medical Center, New York, NY, ³Northwestern Medicine Dermatology, Chicago, IL, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Waukegan, IL, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a progressive condition with chronic inflammation and joint destruction impacting quality of life.1 Dactylitis and enthesitis are clinically relevant domains…
Abstract Number: 2143 • ACR Convergence 2022
Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment
Louis Bessette¹, Georg Pongratz², Luca Navarini³, Rodrigo Garcia Salinas⁴, Tianming Gao⁵, Marie-Claude Laliberté⁶, Ralph Lippe⁷ and Philip J Mease⁸, ¹Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ²Asklepios Clinic Bad Abbach, University of Regensburg, Regensburg, Germany, ³Rheumatology, Immunology, and Clinical Medicine, Department of Medicine, Campus Bio-Medico University of Rome, Rome, Italy, ⁴Hospital Italiano de La Plata, La Plata, Argentina, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Québec, QC, Canada, ⁷AbbVie, Inc, Wiesbaden, Germany, ⁸Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Managing pain, a predominant symptom of psoriatic arthritis (PsA), is a priority for patients and healthcare providers. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor,…
Abstract Number: 0129 • ACR Convergence 2022
Effectiveness of Golimumab in the Treatment of Patients with Active Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis Who Failed Initial TNFα Therapy: A Pooled Analysis of European Prospective Observational Studies (the GO BEYOND Program)
Marinella Govoni¹, Anastas Batalov², Dimitrios Boumpas³, Salvatore D'Angelo⁴, Filip De Keyser⁵, Rene-Marc Flipo⁶, Herbert Kellner⁷, Hermine Leroi⁸ and Ahmed Khalifa⁹, ¹MSD Italy, Cento, Italy, ²Medical University of Plovdiv, Plovdiv, Bulgaria, ³National and Kapodistrian University of Athens, Heraklion, Greece, ⁴Rheumatology Department of Lucania - San Carlo Hospital of Potenza, Potenza, Italy, ⁵Department of Rheumatology, Ghent University Hospital, Maldegem, Belgium, ⁶CHU Lille, Boulogne-Billancourt, France, ⁷Schwerpunktpraxis für Rheumatologie und Gastroenterologie, Munich, Germany, ⁸MSD Belgium, Woluwe-Saint-Lambert, Belgium, ⁹MSD Sharp & Dohme GmbH, Germany, Kriens, Switzerland
Background/Purpose: Patients with inflammatory arthritis often experience secondary non-response to a first-line tumor necrosis factor alpha inhibitor (TNFαi). GO-BEYOND is a study program comprised of…
Abstract Number: 0395 • ACR Convergence 2022
How Does Body Mass Index Affect Secukinumab Treatment Outcomes and Safety in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Juergens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵, Christina Budden⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany, ⁴Medizinische Hochschule Hannover, Hannover, Germany, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany
Background/Purpose: There is a higher prevalence of obesity in patients (pts) with psoriatic disease1. The German non-interventional study AQUILA provides real-world data on the influence…
Abstract Number: 1004 • ACR Convergence 2022
SPARCC, MASES, LEI and MEI Indexes Capture Different Patients with Enthesitis in Axial Spondyloarthritis, Peripheral Spondyloartrhitis and Psoriatic Arthritis
Raquel Granados¹, lourdes Ladehesa-Pineda², Maria Angeles Puche Larrubia³, Maxime Dougados⁴, Eduardo Collantes⁵ and Clementina Lopez-Medina⁶, ¹Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ²Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, ⁴Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ⁶Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain
Background/Purpose: Spondyloarthritis, (axial (axSpA), peripheral (pSpA)) and psoriatic arthritis (PsA)) share enthesitis as a hallmark clinical feature. Reliable clinical instruments have been developed to assess…
Abstract Number: 1036 • ACR Convergence 2022
Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by History of Cigarette Smoking
Alexis Ogdie¹, Lars Erik Kristensen², Enrique R Soriano³, Servet Akar⁴, Yanhui Sun⁵, David Gruben⁶, Lara Fallon⁷, Cassandra D Kinch⁸ and Dafna Gladman⁹, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²The Parker Institute, Copenhagen University Hospital, Copenhagen, Denmark, ³Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁵Pfizer CRDC, Shanghai, China, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Montréal, QC, Canada, ⁸Pfizer Canada ULC, Kirkland, Canada, ⁹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: In patients (pts) with PsA and AS, smoking may be associated with an increased comorbidity burden, and greater responses to TNF inhibitors (TNFi) are…
Abstract Number: 1209 • ACR Convergence 2022
Impact of Change in Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Psoriatic Arthritis Patients
Zhaohui Su¹, Lauren Stevens², Tom Brecht¹, Jessica Paulus¹ and Stefan Weiss³, ¹OM1, Inc., Boston, MA, ²OM1, Inc., Lexington, KY, ³OM1, Inc., Chapel Hill, NC
Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARDs (nDMARD), there is a need for to…
Abstract Number: 1493 • ACR Convergence 2022
Impact of Delay of Treatment with Disease Modifying Antirheumatic Drugs (DMARDs) in Psoriatic Arthritis: Lessons from the CorEvitas PsA/SpA Registry
Philip J Mease¹, Miroslawa Nowak², Jiyoon Choi³, Tom Lehman², Antoine Sreih⁴, Taylor Blachley⁵, Blessing Dube⁵, Kaylee Ho⁵, Nicole Middaugh⁵ and Alexis Ogdie⁶, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Bristol Myers Squibb, Princeton, NJ, ³Bristol Myers Squibb, Lawrenceville, NJ, ⁴Bristol Myers Squibb, Philadelphia, PA, ⁵CorEvitas, LLC, Waltham, MA, ⁶Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is evidence that a delay between psoriatic arthritis (PsA) symptom onset and diagnosis contributes to worse outcomes, yet the impact of delayed DMARD…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].